Steven George Hughes - 06 Jan 2025 Form 3 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Medical Officer
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
06 Jan 2025
Net transactions value
$0
Form type
3
Filing time
08 Jan 2025, 18:46:20 UTC
Next filing
23 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RNA Common Stock 61,375 06 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNA Stock Option (Right to Buy) 06 Jan 2025 Common Stock 64,751 $6.57 Direct F2
holding RNA Stock Option (Right to Buy) 06 Jan 2025 Common Stock 80,167 $22.47 Direct F3
holding RNA Stock Option (Right to Buy) 06 Jan 2025 Common Stock 92,750 $10.16 Direct F4
holding RNA Stock Option (Right to Buy) 06 Jan 2025 Common Stock 84,625 $15.96 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 4,625 RSUs on each of the first four anniversaries of January 20, 2023; 5,625 RSUs on each of the first four anniversaries of January 20, 2024; and 25,000 RSUs on March 19, 2025, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F2 This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.
F3 This option was granted on January 20, 2023 and vests in equal installments of 3,083 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.
F4 This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.
F5 This option was granted on February 14, 2022 and vests in equal installments of 5,652 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on February 14, 2026.